SOX9 is a dose-dependent metastatic fate determinant in melanoma.
Xintao YangRui LiangChunxi LiuJessica Aijia LiuMay Pui Lai CheungXuelai LiuOn Ying ManXin-Yuan GuanHong Lok LungMartin C H CheungPublished in: Journal of experimental & clinical cancer research : CR (2019)
These results unravel NEDD9 as a common target for SOX10 or high SOX9 to partly mediate their oncogenic events, and most importantly, reconcile previous discrepancies that suboptimal level of SOX9 expression is anti-metastatic whereas high level of SOX9 is metastatic in a heterogeneous population of melanoma.